CHARLESTON, SC / ACCESSWIRE / June 27, 2024 / Nordic Wellness, a leading provider of health and wellness solutions, is pleased to announce the acquisition of Peak Flow, a lifestyle breathwork and meditation app. As part of the company's strategic expansion, Peak Flow will be rebranded as Nordic Flow and integrated into Nordic Wellness's portfolio of health and wellness brands. This acquisition marks a significant milestone, enabling Nordic Wellness to offer a comprehensive range of solutions aimed at enhancing both physical and mental well-being.
Nordic Bioproducts Group announces that its new manufacturing factory in Lappeenranta, Finland, has received the prestigious EXCiPACT certification for the production of microcrystalline cellulose (MCC). This certification is a testament to its unwavering commitment to exceeding industry standards in quality, safety, and excellence in production.
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Appoints Oculoplastic Surgeon, John P. Fezza to Medical Advisory Board
Nordic Pharma Completes Acquisition of Visant Medical
TORONTO--(BUSINESS WIRE)--NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet® for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy. Methotrexate is considered a cornerstone therapy for patients with rheumatoid arthritis (RA), with well-established safety and efficacy profiles and support in international guidelines.
HOOFDDORP, Netherlands, Jan. 31, 2022 /PRNewswire/ -- Nordic Pharma announces that on the 24th of January, the European Commission (EC) approved the new indication for Teysuno® (tegafur/gimeracil/oteracil) for the treatment of patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to specific toxicities: hand-foot syndrome and cardiotoxicity.
OSLO, Norway, Dec. 1, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).
Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients